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Background: Certolizumab pegol, a PEGylated tumour necrosis factor (TNF)-inhibitor, improves the clinical signs
and symptoms of rheumatoid arthritis (RA) when used in combination with methotrexate or as monotherapy. This
study evaluatedthe cost-utility of certolizumab pegol versusTNF-inhibitors plus methotrexate in the treatment of
moderate-to-severe RA in Spain.
Methods: A Markov cohort health state transition model was developed to evaluate the cost-utility (costs and
quality-adjusted life years [QALYs]) of certolizumab pegol versus other TNF-inhibitors licensed in Spain in 2009.
Efficacy was measured using the American College of Rheumatology (ACR) responses at 6 months, based on adjusted
indirect comparisons from published clinical trials. Utilities were derived from EQ-5D data from certolizumab pegol RA
clinical trials. Clinical history and resource use data came from published literature. Unit costs were taken from Spanish
databases or published data (cost year 2009). Base case analyses were conducted from the payer perspective, with a
lifetime horizon, 3.5 % annual discounting rates for costs and outcomes, and 3 % inflation rate for 2009 onwards.
One-way sensitivity analyses were conducted.
Results: The average lifetime costs for certolizumab pegol, etanercept, adalimumab (every 2 weeks and weekly)
and infliximab (3 mg/kg and 5 mg/kg) in combination with methotrexate were €140,971, €141,197, €139,148,
€164,741, €136,961 and €152,561, respectively. The QALYs gained were 6.578, 6.462, 6.430 (for both adalimumab
doses), 6.430, and 6.318 (for both infliximab doses), respectively. At a €30,000/QALY willingness-to-pay threshold,
certolizumab pegol plus methotrexate dominated adalimumab weekly, etanercept, and infliximab 5 mg/kg, and
was cost-effective versus adalimumab every 2 weeks and infliximab 3 mg/kg (all with methotrexate), with estimated
ICERs of €12,346/QALY and €15,414/QALY, respectively. Certolizumab pegol monotherapy was more cost-effective
versus adalimumab, and less expensive with similar health gains versus etanercept (6.416 QALYs vs 6.492). Univariate
analysis showed ICERs to be sensitive to changes in time horizon, ACR response time point, baseline Heath Assessment
Questionnaire (HAQ) score, and rate of HAQ-disability index deterioration after discontinuing treatment.
Conclusions: This analysis shows that certolizumab pegol is cost-effective compared with other TNF-inhibitors
recommended in Spain for the treatment of RA.* Correspondence: Alvaro.Hidalgo@uclm.es
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Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease causing progressive joint destruction, deformity and
disability. Although its exact aetiology is unknown, RA
is believed to be an autoimmune disease stimulated by
environmental factors in genetically susceptible individ-
uals [1]. The prevalence in Spain is 0.5 % according to
the EPISER study [2], with an incidence estimated at 8.3
cases per 100,000 by the Spanish Society of Rheumatology.
The annual incidence of RA in adults in Spain is in the
lower range for European countries, and comparable with
those in other Mediterranean countries [3].
The aim of treatment is disease remission or the lowest
disease activity possible. Standard treatment for RA pa-
tients in Spain with persistent disease in spite of aggressive
management currently consists of disease-modifying anti-
rheumatic drugs (DMARDs). In line with national guide-
lines, methotrexate, a small-molecule DMARD, is the first
treatment choice in Spain for more than 80 % of patients
with RA [4]. Biological DMARDs include tumour necrosis
factor (TNF) inhibitors, e.g. certolizumab pegol, adali-
mumab, golimumab, infliximab and etanercept, which
target TNFα, a proinflammatory cytokine believed to
play a major role in the pathogenesis of RA [5]. TNF
inhibitors or tocilizumab, an antibody directed against
the interleukin-6 receptor, administered alone or in com-
bination with methotrexate, are the first treatment option
after small-molecule DMARDs [6, 7]. Other biological
agents used in Spain are anakinra, abatacept and rituxi-
mab, which are used in patients with RA who do not
respond to methotrexate and in patients with active RA
despite treatment with TNF inhibitors [6, 7]. However,
a significant proportion of patients has an unsatisfac-
tory response to these treatments and continues to
experience episodes of disease activity while receiving
therapy [8–11].
Certolizumab pegol (Cimzia®, CZP) is a PEGylated
Fc-free anti-TNF approved for adults with moderate to
severe RA [12, 13]. It is administered by subcutaneous
injection and has a relatively long elimination half-
life, allowing administration once every 2 or 4 weeks.
Certolizumab pegol demonstrated rapid and sustained
improvements in physical function and signs and
symptoms of RA, and relief in pain and fatigue and
significant improvements in productivity at work and
home and participation in social activities [14–17].
CZP is approved in Spain, either as monotherapy or in
combination with methotrexate, for the treatment of
moderate-to-severe, active RA in adult patients when
the response to DMARDs, including methotrexate, has
been inadequate [13].
Whilst TNF inhibitors have generally been shown to
be cost-effective in the treatment of RA [18–26], data
regarding the relative cost-effectiveness of the variousTNF inhibitors are limited and there are few published
economic evaluations for certolizumab pegol.
The aim of this study was to evaluate the cost utility
of certolizumab pegol compared with other standard
first-line TNF-inhibitor therapies licensed and marketed
in Spain in 2009 (etanercept, adalimumab, infliximab),
administered with or without methotrexate for the treat-
ment of patients with moderate-to-severe RA who have
had an inadequate response to methotrexate alone.
Methods
Cost-utility model
The economic evaluation was carried out using a theor-
etical cost-utility analysis framework, using a Markov
model structure (cohort health state transition model)
[27]. Patients entered the model at commencement of
therapy with certolizumab pegol or a comparator. Two
certolizumab pegol regimes were analysed: certolizumab
pegol (400 mg administered on weeks 0, 2 and 4, then
200 mg every 2 weeks) in combination with methotrex-
ate or as monotherapy. Comparators considered in the
analysis were TNFα inhibitors licensed and recom-
mended in Spain in 2009. These included etanercept
(25 mg twice weekly), adalimumab (40 mg every 2 weeks
or 40 mg weekly), infliximab (3 or 5 mg/kg at week 0,
2, 6 and every 8 weeks thereafter), and etanercept or
adalimumab monotherapies.
The population entering the model consisted of pa-
tients that had active RA (defined as a disease activity
score [DAS28] >5.1, confirmed on at least two occasions
a month apart) and had failed to respond adequately to
methotrexate. Baseline characteristics were reflective of
those patients in clinical practice who are eligible for
treatment with certolizumab pegol.
The model was developed with a 6-months or a 3-
months cycle, depending on when the clinical response
is assessed (Fig. 1). At the end of the first cycle, patients
were assigned to 1 of 4 response groups, defined accord-
ing to American College of Rheumatology (ACR) criteria:
no response, ACR20, ACR50 or ACR70 response. In pa-
tients with an inadequate response (no ACR20 response),
treatment was discontinued; only patients who obtained
an adequate response in the first time step continued on
to the modelled initial therapy. Mortality rates are also
assumed during the first cycle of the model [28]. At the
end of the next and following cycles, patients may have
remained in the same Markov treatment health state; dis-
continued treatment due to lack of efficacy or due to an
adverse event; or died. Patients who discontinued treat-
ment were assumed to have moved on to alternative
therapies. On discontinuation of certolizumab pegol or
the comparator treatment (adalimumab, etanercept or
infliximab), patients may have received the following
sequence of conventional DMARD as follow-up therapy:
Fig. 1 Structure of the Markov model. a Follow-up treatment states: duplicated for each follow-up treatment. Patients not responding in the first
6 months of follow-up treatment move to the next treatment in the sequence. b Reason for discontinuation (lack of efficacy or adverse events)
determined by the probabilities after leaving treatment health state
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xychloroquine, azathioprine, cyclosporine, and penicilla-
mine. Upon discontinuation of the last treatment in the
sequence, patients received palliative therapy.
After the first 12 months, cycle duration was six months
to reflect monitoring frequency recommendations by the
Spanish Rheumatology Society [7], the National Institute
for Health and Clinical Excellence (NICE) and the British
Society of Rheumatology (BSR) [29–31].
Incremental cost-effectiveness ratios (ICERs) are pre-
sented, representing the incremental costs necessary to
achieve an additional QALY with certolizumab pegol
versus the comparator selected.
Clinical effectiveness estimates and model assumptions
The natural history of the disease and the data on use of
resources were derived from various sources, including
previous economic evaluation [32]. Treatment duration
was obtained from a study with over 2300 patients
treated with a TNFα inhibitor over 9 years, which
showed that the median treatment duration for TNFα
inhibitors was 37 months (3.08 years) [33]. The duration
of treatment with small-molecule DMARDs was taken
from Chen et al. [32], and all-cause mortality rates for
the general population were obtained from published
age- and gender-specific mortality rates in Spain [34],
adjusted according to Health Assessment Questionnaire-
Disability Index (HAQ-DI). The starting mortality rate
in cycle 1 is adjusted to the age and gender distribution
of the model population and adjustment is made in each
model cycle to represent the increased risk of death aspatients become older. The base case estimate of relative
risk of death of 1.330 per HAQ unit (95 % CI 1.099 to
1.610) is taken from a 35 year cohort study of 3501 RA
patients in Canada [35].
Since there were no head-to-head studies directly
comparing certolizumab pegol efficacy to that of the
other anti-TNF agents, the relative efficacy of the com-
parators was estimated via an indirect analysis of data
from certolizumab pegol studies (RAPID 1 [16, 17],
RAPID 2 [36] and FAST4WARD [14]) and from pub-
lished literature identified through a systematic review
[32] included studies of all biological DMARDs pub-
lished up to April 2009. Medline, Embase and the
Cochrane Library (NHSEED) were searched to identify
studies of certolizumab pegol, adalimumab, etanercept
and infliximab in patients with rheumatoid arthritis.
Other forms of arthritis were excluded as were non-
English language studies. Studies of the following de-
sign were included: economic evaluations piggy-backed
on to a clinical trial; cost-consequence, cost-benefit,
cost-effectiveness, cost-utility and cost-minimisation ana-
lyses; studies in which the comparator was a biological
DMARD or a conventional DMARD; and studies that re-
ported quality of life and cost estimates, cost estimates or
cost-effectiveness.
Abstracts were first screened by two independent
reviewers and any disagreements resolved by a third
reviewer. Duplicate citations and those which did not
match the eligibility criteria were excluded. Full-text
copies of all included and ambiguous studies were ob-
tained. Data from all included studies were extracted
Table 1 Probabilities of transition of the model. Absolute
effectiveness: American College of Rheumatology (ACR)
response rates (%) at 3 and 6 months estimated from published
clinical studies (references cited are the clinical studies upon
which the estimates were based)
3 months 6 months
ACR20 ACR50 ACR70 ACR20 ACR50 ACR70
Combination therapies
MTX [9, 17, 36–43, 61–63]
21.5 7.2 2.0 24.2 9.7 3.7
CZP +MTX [16, 17, 36]
71.1 35.9 21.6 77.2 49.2 28.2
ADA +MTX [9, 37, 41]
70.8 na na 61.0 41.8 19.7
ETA +MTX [38, 39]
66.4 61.1 23.7 68.5 66.4 30.7
IFX +MTX [40, 42, 43]
58.6 27.0 19.6 48.2 26.1 11.3
Monotherapies
Placebo [14, 44–47]
14.0 3.2 1.1 13.1 5.7 1.0
CZP [14]
53.3 45.1 11.6 55.9 31.4 12.3
ADA [44, 45, 47]
55.3 25.7 16.4 39.0 18.8 8.5
ETA [46]
46.2 21.4 5.1 62.0 42.3 12.9
ADA adalimumab, CZP certolizumab pegol, ETA etanercept, IFX infliximab, MTX
methotrexate, na not available
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ments when extracted data were compared resolved
by a third reviewer. Most data came from trials of
biological DMARDs versus methotrexate or placebo.
Two direct trials comparing etanercept with inflixi-
mab as combination therapies with methotrexate were
excluded from the indirect analysis due to their small
patient numbers.
RAPID 1 (52-weeks) and RAPID 2 (24-weeks) were
both phase III, multicentre, double-blind, randomised
placebo-controlled trials evaluating certolizumab pegol
400 mg at weeks 0, 2 and 4 followed by 200 mg or 400 mg
plus methotrexate every 2 weeks, or placebo plus metho-
trexate, in patients with active RA (n = 982 and 619, re-
spectively) [16, 17, 36]. Similarly, FAST4WARD was a
24-week, multicentre, double-blind, placebo-controlled
phase III study, evaluating certolizumab pegol 400 mg
monotherapy every 4 weeks or placebo (n = 220) [14].
ACR20 response rate at week 24 was the primary endpoint
in all three studies (and co-primary in RAPID 1 study).
In addition to the RAPID 1 and RAPID 2 trials, data
for the analysis of combination therapies, with respect to
ACR responses at 3 months, were provided by 4 studies.
These included one study of adalimumab [37], two of
etanercept [38, 39] and one of infliximab [40]. Data on
ACR response rates at 6 months were derived from 6
studies, including three studies of adalimumab [9, 37, 41],
one of etanercept [39] and two of infliximab [42, 43].
All studies were randomised, double-blind, placebo-
controlled studies, except for the study by Westhovens
et al. [43], in which patients in the placebo group crossed
over to receive active treatment between weeks 22–46.
Data for the analysis of monotherapies were provided
by the FAST4WARD study and 3 additional studies each
for ACR response rates at 3 and 6 months. The studies
from which 3-month ACR response rates were derived
included two studies of adalimumab [44, 45] and one
study of etanercept [46]; and 6-month ACR response rates
were derived from two studies of adalimumab [44, 47] and
one of etanercept [46]. All studies were randomised,
double-blind, placebo-controlled studies. Estimated ACR
response rates, i.e. probabilities of transition of the model,
for all agents following the indirect comparison are shown
in Table 1.
Data regarding the safety of biological DMARDs var-
ied in the published literature, in terms of the way it is
reported and analysed, making it difficult to make indir-
ect comparison between different treatments. However,
since safety profiles for all TNF inhibitors, including cer-
tolizumab pegol, appear to be similar, costs and results
associated with adverse events were not explicitly in-
cluded in the model.
Resource use data were taken from published litera-
ture and unit costs (drug acquisition and administration,monitoring and resources) were taken from official
Spanish sources or published references [48, 49]. Treat-
ment unit costs are shown in Table 2 and resource unit
costs are shown in Table 3. The cost of methotrexate
was assumed to be zero and indirect costs were not in-
cluded in the model. Costs per HAQ category were
taken from a cohort study in Sweden and the United
Kingdom [50].
Health effects were measured using the EuroQol
Group 5 Dimension self-report questionnaire (EQ-5D).
Upon entry into the model, the patient population was
assigned a mean pre-treatment utility score of 0.38, de-
rived from the EQ-5D data collected in the certolizumab
pegol RAPID 1 and 2 trials [17, 36]. Over the first
6 months of initial treatment, patients were assigned an
average change in the derived EQ-5D utilities which was
dependent on their response category (Fig. 2). The mag-
nitude of the change in EQ-5D utilities was estimated
from the patient-level data of the certolizumab pegol
trials by ANACOVA regression analysis and the effect is
Table 2 Treatment unit costs in 2009 [48, 49]
Intervention Route of administration Cost (€) Presentation Strength (mg)
TNF inhibitor
CZP SC inj 474 Pre-filled syringe 200
IFX IV inf 536.28 Vial 100
ADA SC inj 514.15 Pre-filled syringe 40
ETA SC inj 118.40 Pre-filled syringe 25
Conventional DMARDs
MTX Oral 2.11 50 tablets 3
Azathioprine Oral 5.78 50 tablets 50
Cyclosporine Oral 65.90 30 tablets 100
Auranofin/gold sodium thiomalate IM inj 6.73 1 vial 50
Hydroxychloroquine Oral 7.33 30 tablets 200
Leflunomide Oral 57.59 30 tablets 20
Penicillamine Oral 6.75 30 tablets 250
Sulfasalazine Oral 2.38 50 tablets 500
Palliative care – 0 – –
Methylprednisolone IV inf 1.59 1 vial 40
ADA adalimumab, CZP certolizumab pegol, ETA etanercept, IFX infliximab, IM intramuscular, INF infusion, INJ injection, IV intravenous, MTX methotrexate,
SC subcutaneous
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models were fitted with age, gender, baseline EQ-5D util-
ities, disease duration, number of previous conventional
DMARDs and anti-CCP antibody status as covariates. De-
fault estimates are adjusted for the selected analysis popu-
lation and are varied in probabilistic sensitivity analyses.
Regression coefficients were then used to calculate the
change in utility. The base-case analysis also assumes that
80 % of the change over the first 6 months is achieved by
week 4. Patients continuing treatment continue to improveTable 3 Resource unit costs in 2009 [64]
Resource Cost (€) Des
Appointments with healthcare personnel and personnel time
Primary care physician 26.78 Gen
Nurse (outpatient clinic) 23.77 Nur
Hospital nurse 13.19 Cos
Rheumatologist 99.94 Rhe
Hospital pharmacist 105.66 Trea
Administration of IV medication in day hospital 232.80 Day
Analysis
Complete blood count 6.37 Com
Sedimentation rate 3.56 Sed
Clinical chemistry profile 6.31 Bloo
Urinalysis 4.00 Urin
Chest X-ray 11.61 Che
IV intravenous, XHUP Xarxa d’Hospitals d’Utilització Pública [Catalan Public Hospitalsover the year following the initial 6 months of treatment,
but at a much smaller rate, as the majority of health benefit
has been gained by this point (Fig. 2). This assumption was
validated by expert clinicians who agreed that it was likely
that patients would continue to improve beyond the first
round of direct clinical improvements as quality of life im-
pact then becomes more important. Again, it is assumed
that certolizumab pegol and all comparators would per-
form similarly. Changes in HAQ-DI scores with time on
treatment are estimated directly from the certolizumabcription
eral medical appointment
sing appointment in general medicine (planned appointment)
t per hour nursing auxiliary, XHUP (total)
umatology
tment rheumatology day hospital (drug and material cost will be added)







Fig. 2 Utilities modelling
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mapped to EQ-5D utility benefit in the model through the
Bansback conversion factor (ΔEQ-5D utility = −0.2102
ΔHAQ) [51]. Patients discontinuing treatment were
assigned a decrease in utility equal to that applied for
the initial response to treatment and an increase in
utility as for the initial response to the first-line treatment,
to account for the benefit of the treatment to which the
patient moves. Thus the model does not favour interven-
tions from which there is low discontinuation, since the
benefit of initial treatment is replaced by a benefit of
follow-up treatments. For the follow-on alternative treat-
ments (conventional DMARDs or palliation) the model
assumes a decline in the health state over time (Fig. 2).
Base-case analysis
The base-case analysis was conducted from the perspec-
tive of the Spanish National Health System (Sistema
Nacional de Salud) and included the following direct
healthcare costs: treatment (unit cost, administration,
monitoring); hospital costs (outpatient and inpatient);
costs of primary-health and specialist medical appoint-
ments. The base case analysis assumed a clinical re-
sponse at 6 months and was conducted over a lifetime
horizon (set at 45 years). In this model, for drugs for
which the dose is adjusted for patient weight (abatacept,
infliximab, azathioprine and cyclosporine), the weight
distribution of the RA population in certolizumab pegol
trials was used to calculate the percentages of patients
receiving a specified number of vials; a patient-fixed
average weight of 81.4 kg was assumed. An annual discount
rate of 3.5 % was applied for costs and outcomes [52–54].
The analysis assumed a cost per unit approach (i.e. assumes
unused drug was wasted). The cost year was 2009, with an
inflation rate of 3 % for 2009 onwards. Annual inflation
rates for the period 1997 to 2009 were taken from theofficial statistics published by the Instituto Nacional de
Estadística (the Spanish National Statistics Institute) [55].
ICERs were evaluated against a €30,000/QALY willing
ness-to-pay (WTP) threshold [56–58].
Sensitivity analyses
Univariate sensitivity analyses were conducted by vary-
ing different model parameters including ACR response
time of 3 months, costing method (per mg), HAQ-DI
measurements for improvements in quality of life in-
stead of EQ-5D, time horizons, discount rate for health
costs and outcomes, an assumed association of zero be-
tween mortality and HAQ-DI, variation (between 0 and
100 %) in the patient's rate of deterioration on the HAQ-
DI scale after discontinuing treatment, baseline HAQ
scale score, the annual progression on the HAQ scale for
the first-line treatment or continuation treatment.
Probabilistic sensitivity analyses were conducted for
each probabilistic sensitivity analysis, 1000 simulations
were generated using base case assumptions and par-
ameter variability summarised in Table 4. The variables
altered were: clinical effectiveness, mean age, baseline
mean HAQ-DI score, number of previous DMARDs,
disease duration and antibody status (modelled using a
normal distribution), gender (using a beta distribution)
and patient weight (using a certolizumab pegol-related
cumulative distribution function). All other parameters
were held constant. From the results of these simula-
tions, cost-effectiveness planes and cost-effectiveness




Certolizumab pegol plus methotrexate was the most cost-
effective therapy when compared with other biologic
Table 4 Parameters varied through probabilistic sensitivity analysis
Parameter Simulation Source
Clinical effectiveness The log odds of response were simulated from a Normal distribution with mean and standard
deviations derived from the CIs of the network meta-analysis (transformed to a log odds scale).
Indirect analysis results.
Association between
mortality and HAQ-DI score
The relative risk was simulated from a Lognormal distribution with parameters implied by the
point estimate (1.330) and its confidence interval (1.099 to 1.610)
Wolfe et al. [35]
Age (years) Normal distribution defined by the mean (52.165) and the standard error (51.893 to 52.4378) RAPID 1, RAPID 2 and
FAST4WARD
Gender Beta distribution defined by N (1821) and n(1506) RAPID 1, RAPID 2 and
FAST4WARD
Weight A cumulative distribution function derived from CZP-related data. RAPID 1, RAPID 2 and
FAST4WARD




Normal distribution defined by the mean (2.258) and its confidence interval (2.207 and 2.308) RAPID 1, RAPID 2 and
FAST4WARD
Disease duration Normal distribution defined by the mean (6.557) and its confidence interval (6.351 and 6.763) RAPID 1, RAPID 2 and
FAST4WARD




Normal distribution defined by the mean (1.621) and its confidence interval (1.606 and 1.635) RAPID 1, RAPID 2 and
FAST4WARD
Utility weight Sampled from a randomized percentage of population (mean 0.380 and confidence interval
0.372 and 0.388)
RAPID 1 and RAPID 2
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willingness-to-pay (WTP) threshold [56–58]. Certolizu-
mab pegol + methotrexate dominated (most efficient as
assessed through QALYs and less expensive) adalimu-
mab (weekly), etanercept, infliximab 5 mg/kg, combin-
ation therapies. Combination certolizumab pegol plus
methotrexate was cost-effective versus adalimumab (every
2 weeks) and infliximab 3 mg/kg in combination withTable 5 Base case results for the treatment of rheumatoid arthritis i
Mean costs (€) Difference in costs vs CZ
Combination therapies
CZP +MTX 140,971 0
ADA +MTX (every 2 weeks) 139,148 1823
ADA +MTX (weekly) 164,741 −23,770
ETA +MTX 141,197 −226
IFX (3 mg/kg) + MTX 136,961 4010
IFX (5 mg/kg) + MTX 152,561 −11,590
Monotherapies
CZP 134,792 0
ADA (every 2 weeks) 136,745 −1953
ADA (weekly) 156,223 −21,431
ETAa 135,459 667
ADA adalimumab, CZP certolizumab pegol, ETA etanercept, ICER incremental cost-ef
life years
aIncremental Analysis is for ETA versus CZP and not the other way roundmethotrexate, with estimated ICERs of €12,346/QALY and
€15,414/QALY, respectively (see Table 5).
Monotherapies
The analysis indicated that certolizumab pegol mono-
therapy was the most effective (as measured through
QALYs) and less expensive compared with adalimu-
mab (weekly or every 2 weeks). Certolizumab pegoln Spain over a lifetime horizon (45 years)
P (€) Mean QALY Difference in QALYs vs CZP ICER vs CZP
6.578 0 –
6.430 0.148 €12,346
6.430 0.148 CZP dominant
6.462 0.116 CZP dominant
6.318 0.260 €15,414
6.318 0.260 CZP dominant
6.416 0 –
6.216 0.200 CZP dominant
6.216 0.200 CZP dominant
6.492 0.076 €8,778a
fectiveness ratio, IFX infliximab, MTX methotrexate, QALY quality-adjusted
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health gains when compared with etanercept monotherapy
(6.416 QALYs vs 6.492), that lead to an ICER of €8788/
QALY (etanercept vs certolizumab pegol). See Table 5.
Sensitivity analyses
Univariate sensitivity analysis
The results of the analysis of sensibility are show in the
Tables 6 and 7. The sensitivity analyses indicated that
the base case results were robust, with certolizumab
pegol remaining the cost-effective treatment at the
€30.000/QALY WTP threshold, when changes were ap-
plied to the discount rate, economic perspective of the
analysis, the drug costing method, the choice of quality
of life instrument and the association between HAQ
score and mortality. The ICERs were sensitive to
changes in the time horizon, timepoint of ACR response,
baseline HAQ score, and the rate of deterioration in
HAQ-DI scale after discontinuing the treatment.
Probabilistic sensitivity analyses
Cost-effectiveness planes for the PSA of certolizumab
pegol vs. other therapies with the ACR six monthTable 6 One way sensitivity analysis for the ICER of certolizumab pe
Parameter Base case estimate Sensitivity estimate
Base case results
Time horizon Lifetime 5 years
10 years
Discount rate Costs and QALYs 3.5 % Costs 1.5 % and QA
Costs 1.5 % and QA
Costs 6 % and QALY
Costs 6 % and QALY
Inflation 3.0 % 0 %
ACR response 6 months 3 months




100 % 50 %
Perspective SNS Societal
Drug costing Per mg Per unit
Principle QoL instrument EQ-5D HAQ DI
Association between HAQ
DI and mortality
RR of 1.33 per HAQ DI
increment
No association (RR o
Administration Cost of IV
medicationin day hospital
214,54 € +20 % (257,44 €)
−20 % (171,63 €)
aICER is of adalimumab or etanercept against CZP, rather than vice versa, as elsewhdefinition of response are shown in Figs. 3 and 4. The
probabilistic sensitivity analysis indicated that at €30.000/
QALY WTP, certolizumab pegol plus methotrexate has
the highest probability of being cost-effective against
adalimumab (weekly) and infliximab (5 mg/kg), in 91 %
and 78 % of the cases, respectively. When compared with
adalimumab every 2 weeks, etanercept and infliximab
(3 mg/kg), and certolizumab pegol had almost equal
probability of being cost-effective (42 to 48 % at a
€30.000/QALY WTP threshold).
Discussion
The cost utility of certolizumab pegol compared with
other TNF inhibitors available in Spain in 2009 and
administered alone or in combination with methotrexate
in patients with moderate-to-severe RA who have had
an inadequate response to methotrexate alone has been
estimated. Evaluated against a €30,000/QALY WTP
threshold and over a lifetime horizon, certolizumab
pegol administered in combination with methotrexate
was a dominant therapy compared with other TNF
inhibitor combination therapies (weekly adalimumab,
etanercept, and infliximab 5 mg/kg), and cost-effectivegol vs. monotherapies
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Comparator to certolizumab pegol (incremental cost per QALY gained)
Adalimumab
(every 2 weeks) + MTX
Adalimumab
(weekly) + MTX
Etanercept + MTX Infliximab
(3 mg/kg) + MTX
Infliximab
(5 mg/kg) + MTX
Base case results 12,346 CZP dominates CZP dominates 15,414 CZP dominates
Time horizon Lifetime 5 years 36,676 CZP dominates 406,743 27,472 CZP dominates
10 years 29,024 CZP dominates 87,096 24,861 CZP dominates
Discount rate Costs and
QALYs 3.5 %
Costs 1.5 % and
QALYs 1.5 %
7736 CZP dominates CZP dominates 12,924 CZP dominates
Costs 1.5 % and
QALYs 6 %
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Costs 6 % and
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13,621 CZP dominates 6372 14,747 CZP dominates
Costs 6 % and
QALYs 6 %
17,281 CZP dominates 11,624 17,796 CZP dominates
Inflation 3.0 % 0 % 14,385 CZP dominates CZP dominates CZP dominates CZP dominates
ACR response 6 months 3 months 996a 78.117a CZP dominates 5461 CZP dominates
Baseline HAQ score 1.6 1 32,708a 565.932a 8459 50,134 123,991a
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Perspective SNS Societal CZP dominates CZP dominates CZP dominates CZP dominates CZP dominates
Drug costing Per mg Per unit 12,821 CZP dominates CZP dominates 29,538 CZP dominates
Principle QoL
instrument
EQ-5D HAQ DI 9791 CZP dominates 28,013 8709 CZP dominates
Association between






7766 CZP dominates CZP dominates 12,608 CZP dominates















Fig. 3 Plane of incremental costs (£) vs. incremental QALYs and Cost-effectiveness acceptability curve: Certolizumab pegol + MTX vs MTX;
Certolizumab pegol + MTX vs Adalimumab (every 2 weeks) + MTX and Certolizumab pegol + MTX vs Adalimumab (weekly) + MTX
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combination therapies.
Certolizumab pegol monotherapy was dominant ver-
sus weekly or 2-weekly adalimumab monotherapy and
was also less expensive, but had comparable health gains
when compared with etanercept monotherapy. Probabil-
istic sensitivity analyses confirmed the cost-effectiveness
of certolizumab pegol + methotrexate combination ther-
apy. Univariate sensitivity analyses showed that ICERs
for certolizumab pegol administered with or without
methotrexate were robust to changes in the majority of
variables analysed, and that ICERs were sensitive to
changing the time horizon, timepoint of ACR response,
baseline HAQ score, and the rate of deterioration in
HAQ-DI scale after discontinuing the treatment.
Comparison with other studies is difficult since most
of the studies published to date support the cost-
effectiveness of TNF inhibitors as a second-line strategy
in patients who fail to respond to non-biological
DMARDs, but relative evaluation of TNF inhibitorsusing indirect cost-effectiveness analyses are lacking.
Only one study, evaluating the relative cost-effectiveness
of the five current FDA-approved TNFα inhibitors in
combination with methotrexate for the treatment of pa-
tients with moderate-to-severe active RA and with mod-
erate or no response to methotrexate monotherapy from
a US health payer perspective, has been recently pub-
lished [59]. The study used Bayesian methods to deter-
mine the relative probabilities of achieving an ACR50 clinical
response for each TNF inhibitor and Markov modelling, in
which patients who achieved ACR50 criteria continued to
receive combination therapy but those who did not switched
to tocilizumab. Results of the study showed certolizumab
pegol +methotrexate to be the second most cost-effective
TNF inhibitor after etanercept +methotrexate, dominating
infliximab, adalimumab and golimumab combination ther-
apies at a WTP threshold of US$139,143/QALY.
Whilst estimation of relative effectiveness of the vari-
ous biological DMARDs using ACR response data from
only randomised, double-blind trials with methotrexate
Fig. 4 Plane of incremental costs (£) vs. incremental QALYs and Cost-effectiveness acceptability curve: Certolizumab pegol + MTX vs Etanercept +
MTX; Certolizumab pegol + MTX vs Infliximab (3 mg/kg) + MTX and Certolizumab pegol + MTX vs Infliximab (5 mg/kg) + MTX
Hidalgo-Vega et al. Cost Effectiveness and Resource Allocation  (2015) 13:11 Page 11 of 13and/or placebo as controls helped to ensure the quality
of these data, the lack of head-to-head studies, necessi-
tating indirect analysis of ACR response data, is ac-
knowledged as a limitation of our study. Also, although
similar incidences of adverse events between the avail-
able biological DMARDs may be generally considered
to be a reasonable assumption, exclusion of the costs
associated with adverse events from the model is an-
other acknowledged limitation of our study. Other limi-
tations include the lack of data sources and cost-utility
data (in Spain and worldwide) with which to compare
our data, and the limited effectiveness of applying
effectiveness information from 6 months, which is >1
treatment cycle.
The implications of our study findings for the public
payer in Spain suggest that the Spanish NHS would be
adopting the most cost-effective treatment if certolizu-
mab pegol were offered to RA patients in combination
with methotrexate instead of alternative TNF inhibitors
currently recommended in Spain. Furthermore a recentstudy, in that equality of effectiveness is supposed, indi-
cated that the addition of certolizumab pegol on the
NHS in Spain, would generate large net savings of
€10.3 million for the period 2013 to 2017 [60].Conclusions
In our study, in terms of QALYs gained, certolizumab
pegol was the most effective therapy in combination
with methotrexate at the €30,000/QALY willingness-to-
pay (WTP) threshold compared with other TNF inhibitors
recommended in Spain in 2009 (adalimumab, etanercept
and infliximab) for the treatment of patients with active
RA who did not respond adequately to DMARDs. In an
analysis of monotherapies, certolizumab pegol was more
cost-effective versus adalimumab and less expensive with
similar health gains versus etanercept (mean QALY 6.416
vs 6.492). Probabilistic sensitivity analyses indicated advan-
tages in efficacy for certolizumab pegol over the other TNF
inhibitors. These results indicate that moderate-to-severe
Hidalgo-Vega et al. Cost Effectiveness and Resource Allocation  (2015) 13:11 Page 12 of 13RA treatment with certolizumab pegol is an efficient and
economically valuable alternative for the Spanish NHS.
Abbreviations
ACR: American College of Rheumatology; ACR20: American College of
Rheumatology 20 % response; ACR50: American College of Rheumatology
50 % response; ACR70: American College of Rheumatology 70 % response;
DAS28: Disease Activity Score 28; DMARDs: disease-modifying antirheumatic
drugs; EQ-5D: EuroQol Group 5 Dimension; HAQ: Health Assessment
Questionnaire; HAQ-DI: Health Assessment Questionnaire-Disability Index;
ICERs: incremental cost-effectiveness ratios; LYG: life year gained;
QALY: quality-adjusted life year; RA: rheumatoid arthritis; TNF: tumour
necrosis factor; WTP: willingness-to-pay.
Competing interests
Álvaro Hidalgo is a professor at University of Castilla-La Mancha which
received consulting fees for its contribution to this study.
Renata Villoro is a researcher at Max Weber Institute which received
consulting fees for its contribution to this study.
Pablo Talavera and Belén Ferro are employees of UCB Pharma Spain.
Oana Purcaru is an employee of UCB Pharma Belgium.
Juan Antonio Blasco has no competing interests.
Authors’ contributions
OP was responsible for the design and conduct of the cost-utility analysis; PT
and BF were responsible for adapting the model to Spanish data (Spanish
cost, population, etc.) in collaboration with AH, RV and JAB. All authors read
and approved the final manuscript.
Acknowledgments
UCB Pharma, Brussels was responsible for the design and conduct of the
cost-utility analysis; UCB Pharma, S.A. Spain was responsible for adapting the
model to Spanish data (Spanish cost, population, etc.) in collaboration with
Castilla-La Mancha University and Max Weber Institute (with funding from
UCB Pharma S.A., Spain) and with Health Technology Assessment in Spain
(without funding or payments from UCB Pharma S.A., Spain).
Medical writing assistance was provided by Andrea Bothwell of in Science
Communications, Springer Healthcare, with funding from UCB Pharma, S.A.,
Spain.
Author details
1Castilla-La Mancha University, Toledo, Spain. 2Max Weber Institute, Madrid,
Spain. 3Lain Entralgo, Health Technology Assessment, Madrid, Spain. 4Medical
Department, UCB Pharma, Madrid, Spain. 5Market Access-Pharmacoeconomic
Department, UCB Pharma, Madrid, Spain. 6Global Market Access, UCB
Pharma, Brussels, Belgium.
Received: 1 July 2014 Accepted: 3 June 2015
References
1. Disease Management Project: Rheumatoid Arthritis. [http://www.cleveland
clinicmeded.com/medicalpubs/diseasemanagement/rheumatology/
rheumatoid-arthritis/]
2. Carmona L, Ballina J, Gabriel R, Laffon A. The burden of musculoskeletal
diseases in the general population of Spain: results from a national survey.
Ann Rheum Dis. 2001;60:1040–5.
3. Carbonell J, Cobo T, Balsa A, Descalzo MA, Carmona L, Group SS. The
incidence of rheumatoid arthritis in Spain: results from a nationwide
primary care registry. Rheumatology. 2008;47:1088–92.
4. A survey of barriers to treatment access in rheumatoid arthritis. Country
Annex Report: Spain [http://www.comparatorreports.se/
RA%20Barrier%20Report_FINAL_050110.pdf]
5. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid
arthritis. N Engl J Med. 2006;355:704–12.
6. Rodriguez-Valverde V, Caliz Caliz R, Álvaro-Gracia Álvaro JM, Marenco de la
Fuente JL, Mulero Mendoza J, Tornero Molina J, Andreu Sanchez JL, Ballina
Garcia FJ, Batlle Gualda E, Canete Crespillo JD, et al. 3rd update on the
Spanish Rheumatology Society consensus on biological therapy in
rheumatoid arthritis. 2006.7. Tornero Molina J, Sanmarti Sala R, Rodriguez Valverde V, Martin Mola E,
Marenco de la Fuente JL, Gonzalez Alvaro I, et al. [Update of the consensus
statement of the spanish society of rheumatology on the management of
biologic therapies in rheumatoid arthritis]. Reumatologia clinica. 2010;6:23–36.
8. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH,
et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis:
two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46:1443–50.
9. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al.
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a
human anti-tumor necrosis factor monoclonal antibody) in patients with active
rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized,
placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400–11.
10. Klinkhoff A. Biological agents for rheumatoid arthritis: targeting both
physical function and structural damage. Drugs. 2004;64:1267–83.
11. Voll RE, Kalden JR. Do we need new treatment that goes beyond tumor necrosis
factor blockers for rheumatoid arthritis? Ann N Y Acad Sci. 2005;1051:799–810.
12. Cimzia, certolizumab pegol: European Public Assessment Report (EPAR)
summary for the public [http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Summary_for_the_public/human/001037/
WC500069733.pdf]
13. Cimzia 200 mg solution for injection: Summary of Product Characteristics
[http://www.medicines.org.uk/emc/medicine/22323/SPC]
14. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J,
Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy
every 4 weeks in patients with rheumatoid arthritis failing previous
disease-modifying antirheumatic therapy: the FAST4WARD study. Ann
Rheum Dis. 2009;68:805–11.
15. Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, et al.
Effect of certolizumab pegol with methotrexate on home and work place
productivity and social activities in patients with active rheumatoid
arthritis.[Erratum appears in Arthritis Rheum. 2010 Oct;62(10):1514]. Arthritis
Rheum. 2009;61:1592–600.
16. Keystone E, van der Heijde D, Mason Jr D, Landewe R, Vollenhoven RV,
Combe B, et al. Certolizumab pegol plus methotrexate is significantly more
effective than placebo plus methotrexate in active rheumatoid arthritis:
findings of a fifty-two-week, phase III, multicenter, randomized, double-
blind, placebo-controlled, parallel-group study.[Erratum appears in Arthritis
Rheum. 2009 May;60(5):1249]. Arthritis Rheum. 2008;58:3319–29.
17. Strand V, Mease P, Burmester GR, Nikai E, Coteur G, van Vollenhoven R, et al.
Rapid and sustained improvements in health-related quality of life, fatigue,
and other patient-reported outcomes in rheumatoid arthritis patients
treated with certolizumab pegol plus methotrexate over 1 year: results from
the RAPID 1 randomized controlled trial. Arthritis Res Ther. 2009;11:R170.
18. Allaart CF, Breedveld FC, Dijkmans BAC. Treatment of recent-onset rheumatoid
arthritis: lessons from the BeSt study. J Rheumatol. 2007;80:25–33.
19. Barbieri M, Wong JB, Drummond M. The cost effectiveness of infliximab for
severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics.
2005;23:607–18.
20. Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, et al.
Modelling the cost effectiveness of TNF-alpha antagonists in the management
of rheumatoid arthritis: results from the British Society for Rheumatology
Biologics Registry. Rheumatology. 2007;46:1345–54.
21. Davies A, Cifaldi MA, Segurado OG, Weisman MH. Cost-effectiveness of
sequential therapy with tumor necrosis factor antagonists in early rheumatoid
arthritis. J Rheumatol. 2009;36:16–26.
22. Farahani P, Levine M, Goeree R. A comparison between integrating clinical
practice setting and randomized controlled trial setting into economic
evaluation models of therapeutics. J Eval Clin Pract. 2006;12:463–70.
23. Rubio-Terres C, Ordovas Baines JP, Pla Poblador R, Martinez Nieto C,
Sanchez Garre MJ, Rosado Souviron MA, et al. [Use and cost of biological
disease-modifying anti-rheumatic drugs in Spain (PRAXIS study)]. Farm Hosp.
2007;31:78–92.
24. Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ. Cost-effectiveness
of adalimumab, etanercept, and tocilizumab as first-line treatments for
moderate-to-severe rheumatoid arthritis. J Med Econ. 2012;15:340–51.
25. Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-alpha
inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics.
2006;24:1221–32.
26. Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, et al. Modeling
and cost-effectiveness analysis of etanercept in adults with rheumatoid
arthritis in Japan: a preliminary analysis. Mod Rheumatol. 2006;16:77–84.
Hidalgo-Vega et al. Cost Effectiveness and Resource Allocation  (2015) 13:11 Page 13 of 1327. Purcaru O, Taylor P, Emery P, Palmer S. Cost-effectiveness of certolizumab
pegol plus methotrexate or as monotherapy for the treatment of active
rheumatoid arthritis in the United Kingdom [abstract]. Ann Rheum Dis.
2010;69:718.
28. Fries JF. Aging, natural death, and the compression of morbidity. 1980. Bull
World Health Organ. 2002;80:245–50.
29. Briggs A, Sculpher M. An introduction to Markov modelling for economic
evaluation. Pharmacoeconomics. 1998;13:397–409.
30. Luqmani R, Hennell S, Estrach C, Birrell F, Bosworth A, Davenport G, et al.
British Society for Rheumatology and british health professionals in
Rheumatology guideline for the management of rheumatoid arthritis (the
first two years). Rheumatology. 2006;45:1167–9.
31. Costing template for infliximab for the treatment of adults with psoriasis
(Guidance TA134) [http://guidance.nice.org.uk/TA134/CostingTemplate]
32. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A,
Burls A. A systematic review of the effectiveness of adalimumab, etanercept
and infliximab for the treatment of rheumatoid arthritis in adults and an
economic evaluation of their cost-effectiveness. Health Technol Assess
(Winchester, England). 2006; 10:iii-iv, xi-xiii, 1–229.
33. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison
of drug retention rates and causes of drug discontinuation between
anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum.
2009;61:560–8.
34. Mortality Tables for the Spanish Population 1991–2007: Mortality tables for
the Spanish population by year, age, gender and functions [http://www.ine.es/
jaxi/tabla.do?path=/t20/p319a/1991-2007/l0/&file=01001.px&type=pcaxis&L=0]
35. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The
mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37:481–94.
36. Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al.
Efficacy and safety of certolizumab pegol plus methotrexate in active
rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann
Rheum Dis. 2009;68:797–804.
37. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara
CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha
monoclonal antibody, for the treatment of rheumatoid arthritis in patients
taking concomitant methotrexate: the ARMADA trial.[Erratum appears in
Arthritis Rheum. 2003 Mar;48(3):855]. Arthritis Rheum. 2003;48:35–45.
38. Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young Jr M. A comparative
study of etanercept plus methotrexate and methotrexate alone in
Taiwanese patients with active rheumatoid arthritis: a 12-week,
double-blind, randomized, placebo-controlled study. J Formos Med Assoc.
2004;103:618–23.
39. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox
RI, et al. A trial of etanercept, a recombinant tumor necrosis factor
receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving
methotrexate. N Engl J Med. 1999;340:253–9.
40. Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A
multicenter, double-blind, randomized, placebo controlled trial of infliximab
combined with low dose methotrexate in Japanese patients with
rheumatoid arthritis. J Rheumatol. 2006;33:37–44.
41. Kim H. A randomized, double-blind, placebo-controlled, phase III study of
the human anti-tumor necrosis factor antibody adalimumab administered
as subcutaneous injections in Korean rheumatoid arthritis patients treated
with methotrexate. APLAR J Rheumatol. 2007;10:9–16.
42. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S,
et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a
phase III, multi-centre, randomised, double-blind, placebo-controlled study
in patients with rheumatoid arthritis and an inadequate response to
methotrexate. Ann Rheum Dis. 2008;67:1096–103.
43. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The
safety of infliximab, combined with background treatments, among patients
with rheumatoid arthritis and various comorbidities: a large, randomized,
placebo-controlled trial.[Erratum appears in Arthritis Rheum. 2007
May;56(5):1675 Note: Dosage error in article text]. Arthritis Rheum.
2006;54:1075–86.
44. Miyasaka N, Investigators CS. Clinical investigation in highly disease-affected
rheumatoid arthritis patients in Japan with adalimumab applying standard
and general evaluation: the CHANGE study. Mod Rheumatol.
2008;18:252–62.
45. van de Putte LBA, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel
PLCM, et al. Efficacy and safety of the fully human anti-tumour necrosisfactor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory
patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum
Dis. 2003;62:1168–77.
46. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM,
Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized,
controlled trial. Ann Intern Med. 1999;130:478–86.
47. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al.
Efficacy and safety of adalimumab as monotherapy in patients with
rheumatoid arthritis for whom previous disease modifying antirheumatic
drug treatment has failed. Ann Rheum Dis. 2004;63:508–16.
48. BOT Medicines Database [http://www.portalfarma.com/Home.nsf/
Home?OpenForm]
49. Information on products included in the Spanish Health System
pharmaceutical list (can be dispensed by community pharmacists):
Invoicing List for December/2009 [http://www.msssi.gob.es/profesionales/
nomenclator.do]
50. Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modeling the
progression of rheumatoid arthritis: a two-country model to estimate costs
and consequences of rheumatoid arthritis. Arthritis Rheum. 2002;46:2310–9.
51. Modelling the cost effectiveness of TNF-α inhibitors in the management of
rheumatoid arthritis: Results from the British Society for Rheumatology
Biologics Registry [http://www.shef.ac.uk/polopoly_fs/1.43358!/file/HEDS-DP-
06-12.pdf]
52. Puig-Junoy J, Oliva Moreno J, Trapero Beltrán M, Abellan Perpinan JM, Brosa
Riestra M. Guía y recomendaciones para la realización y presentación de
evaluaciones económicas y análisis de impacto presupuestario de medicamentos
en el ámbito del CatSalut. Barcelona: Servei Català de la Salut (CatSalut); 2014.
53. Pinto JL, Sánchez Martínez FI. Métodos para la evaluación económica de
nuevas prestaciones. Madrid, 2007. Madrid: Centre de Recerca en Economia
i Salut y Ministerio de Sanidad y Consumo; 2007.
54. López Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, et al.
Propuesta de guía para la evaluación económica aplicada a las tecnologías
sanitarias. Gac Sanit. 2010;24:154–70.
55. Standard of living, quality of life and living conditions: consumer price index
[http://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&
cid=1254736176802&menu=ultiDatos&idp=1254735976607]
56. Guide to the methods of technology appraisal [http://www.nice.org.uk/
article/pmg9/chapter/Foreword]
57. Rodriguez Barrios JM, Perez Alcantara F, Crespo Palomo C, Gonzalez Garcia
P, Anton De Las Heras E, Brosa Riestra M. The use of cost per life year
gained as a measurement of cost-effectiveness in Spain: a systematic review
of recent publications. Eur J Health Econ. 2012;13:723–40.
58. Sacristan JA, Oliva J, Del Llano J, Prieto L, Pinto JL. [What is an efficient
health technology in Spain?]. Gaceta sanitaria/SESPAS. 2002;16:334–43.
59. Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN,
Kazerooni R, et al. Cost utility of tumour necrosis factor-alpha inhibitors for
rheumatoid arthritis: an application of Bayesian methods for evidence
synthesis in a Markov model. Pharmacoeconomics. 2012;30:575–93.
60. Hidalgo A, Villoro R, Ivanova A, Morell A, Talavera P, Ferro B. Tratamiento
biológico de la Artritis reumatoide en España. Análisis de impacto
presupuestario de la utilización de certolizumab pegol. Pharmacoecon Span
Res Artic. 2014;11:97–107.
61. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind
randomized controlled clinical trial of the interleukin-6 receptor antagonist,
tocilizumab, in European patients with rheumatoid arthritis who had an
incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817–29.
62. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J,
Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab
in patients with rheumatoid arthritis (OPTION study): a double-blind,
placebo-controlled, randomised trial. Lancet. 2008;371:987–97.
63. Strand V, Balbir-Gurman A, Pavelka K, Emery P, Li N, Yin M, et al. Sustained
benefit in rheumatoid arthritis following one course of rituximab:
improvements in physical function over 2 years. Rheumatology.
2006;45:1505–13.
64. eSalud - Financial information on the healthcare sector [http://oblikue.com/
bddcostes/]
